ERBB2 and gastric cancer: Recently, a phase 3 clinical trial named SPOTLIGHT showed that Zolbetuximab, an anti‐claudin 18.2 antibody, improved progression‐free survival (PFS) and overall survival (OS) in claudin 18.2‐positive, HER2‐negative gastric cancer patients (NCT03504397).